Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial

Ihle, 1996, Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial, Am J Kidney Dis, 27, 489, 10.1016/S0272-6386(96)90158-4 1997, Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy, Lancet, 349, 1857, 10.1016/S0140-6736(96)11445-8 Ruggenenti, 1998, Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial, Lancet, 352, 1252, 10.1016/S0140-6736(98)04433-X Lewis, 1993, The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy, N Engl J Med, 329, 1456, 10.1056/NEJM199311113292004 de Zeeuw, 2004, Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL, Kidney Int, 65, 2309, 10.1111/j.1523-1755.2004.00653.x Nagase, 2006, Enhanced aldosterone signalingin the early nephropathy of rats with metabolic syndrome: possible contribution of fat derived factors, J Am Soc Nephrol, 17, 3438, 10.1681/ASN.2006080944 Nagase, 2006, Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker, Hypertension, 47, 1084, 10.1161/01.HYP.0000222003.28517.99 White, 2003, Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension, Hypertension, 41, 1021, 10.1161/01.HYP.0000067463.13172.EA Williams, 2004, Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension, Am J Cardiol, 93, 990, 10.1016/j.amjcard.2004.01.007 Rossing, 2005, Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study, Diabetes Care, 28, 2106, 10.2337/diacare.28.9.2106 Sato, 2003, Effectiveness of aldosterone blockade in patients with diabetic nephropathy, Hypertension, 41, 64, 10.1161/01.HYP.0000044937.95080.E9 Epstein, 2006, Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes, Clin J Am Soc Nephrol, 1, 940, 10.2215/CJN.00240106 Mehdi, 2009, Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy, J Am Soc Nephrol, 20, 2641, 10.1681/ASN.2009070737 Yano, 2011, Efficacy of eplerenone added to renin-angiotensin blockade in elderly hypertensive patients: the Jichi-Eplerenone Treatment (JET) study, J Renin Angiotensin Aldosterone Syst, 12, 340, 10.1177/1470320310390404 Ando, 2010, Hypertens Res, 33, 616, 10.1038/hr.2010.46 Schulz, 2010, CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials, Ann Intern Med, 152, 726, 10.7326/0003-4819-152-11-201006010-00232 Matsuo, 2009, Revised equations for estimated GFR from serum creatinine in Japan, Am J Kidney Dis, 53, 982, 10.1053/j.ajkd.2008.12.034 Kawasaki, 1993, A simple method for estimating 24 h urinary sodium and potassium excretion from second morning voiding urine specimen in adults, Clin Exp Pharmacol Physiol, 20, 7, 10.1111/j.1440-1681.1993.tb01496.x Hollenberg, 2004, Aldosterone in the development and progression of renal injury, Kidney Int, 66, 1, 10.1111/j.1523-1755.2004.00701.x McCarron, 2013, Normal range of human dietary sodium intake: a perspective based on 24-hour urinary sodium excretion worldwide, Am J Hypertens, 26, 1218, 10.1093/ajh/hpt139 Jafar, 2001, Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data, Ann Intern Med, 135, 73, 10.7326/0003-4819-135-2-200107170-00007 Levey, 2009, Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration, Am J Kidney Dis, 54, 205, 10.1053/j.ajkd.2009.04.029 de Zeeuw, 2011, CKD treatment: time to alter the focus to albuminuria?, Adv Chronic Kidney Dis, 18, 222, 10.1053/j.ackd.2011.06.005 Bomback, 2007, The incidence and implications of aldosterone breakthrough, Nat Clin Pract Nephrol, 3, 486, 10.1038/ncpneph0575 Vegter, 2012, Sodium intake, ACE inhibition, and progression to ESRD, J Am Soc Nephrol, 23, 165, 10.1681/ASN.2011040430 Vogt, 2008, Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan, J Am Soc Nephrol, 19, 999, 10.1681/ASN.2007060693 Shibata, 2011, Rac1 GTPase in rodent kidneys is essential or salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway, J Clin Invest, 121, 3233, 10.1172/JCI43124 Shibata, 2008, Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease, Nat Med, 14, 1370, 10.1038/nm.1879 Fu, 2012, Aldosterone blunts tubuloglomerular feedback by activating macula densa mineralocorticoid receptors, Hypertension, 59, 599, 10.1161/HYPERTENSIONAHA.111.173195 Epstein, 2009, Hyperkalemia as a constraint to therapy with combination renin-angiotensin system blockade: the elephant in the room, J Clin Hypertens, 11, 55, 10.1111/j.1751-7176.2008.00071.x Shavit, 2012, Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms, Kidney Int, 81, 955, 10.1038/ki.2011.505 Fried, 2013, Combined angiotensin inhibition for the treatment of diabetic nephropathy, N Engl J Med, 369, 1892, 10.1056/NEJMoa1303154 Gaede, 2008, Effect of a multifactorial intervention on mortality in type 2 diabetes, N Engl J Med, 358, 580, 10.1056/NEJMoa0706245 Rossing, 2005, Enhanced renoprotective effects of ultra-high doses of irbesartan in patients with type 2 diabetes and microalbuminuria, Kidney Int, 68, 1190, 10.1111/j.1523-1755.2005.00511.x Mente, 2014, Validation and comparison of three formulae to estimate sodium and potassium excretion from a single morning fasting urine compared to 24-h measures in 11 countries, J Hypertens, 32, 1005, 10.1097/HJH.0000000000000122